



**Cite this article:** Bennett A, Sloss O, Topham C, Nelson L, Tighe A, Taylor SS. 2016 Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. *Open Biol.* **6**: 160134. <http://dx.doi.org/10.1098/rsob.160134>

Received: 3 May 2016

Accepted: 8 July 2016

## Subject Area:

cellular biology

## Keywords:

apoptosis, spindle checkpoint, paclitaxel, taxol, WEHI-539

## Author for correspondence:

Stephen S. Taylor

e-mail: [stephen.taylor@manchester.ac.uk](mailto:stephen.taylor@manchester.ac.uk)

<sup>†</sup>Present address: School of Environment and Life Sciences, University of Salford, Salford M5 4WT, UK.

Electronic supplementary material is available at <http://dx.doi.org/10.1098/rsob.160134>.

# Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers

Ailsa Bennett, Olivia Sloss, Caroline Topham<sup>†</sup>, Louisa Nelson, Anthony Tighe and Stephen S. Taylor

Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester M20 4QL, UK

SST, 0000-0003-4621-9326

Cell fate in response to an aberrant mitosis is governed by two competing networks: the spindle assembly checkpoint (SAC) and the intrinsic apoptosis pathway. The mechanistic interplay between these two networks is obscured by functional redundancy and the ability of cells to die either in mitosis or in the subsequent interphase. By coupling time-lapse microscopy with selective pharmacological agents, we systematically probe pro-survival Bcl-xL in response to various mitotic perturbations. Concentration matrices show that BH3-mimetic-mediated inhibition of Bcl-xL synergises with perturbations that induce an SAC-mediated mitotic block, including drugs that dampen microtubule dynamics, and inhibitors targeting kinesins and kinases required for spindle assembly. By contrast, Bcl-xL inhibition does not synergize with drugs which drive cells through an aberrant mitosis by overriding the SAC. This differential effect, which is explained by compensatory Mcl-1 function, provides opportunities for patient stratification and combination treatments in the context of cancer chemotherapy.

## 1. Introduction

Antimitotic agents including the taxanes and vinca alkaloids are used extensively to treat numerous malignancies, including ovarian and breast cancer as well as various leukaemias [1]. Patient responses are, however, unpredictable; some cancers are intrinsically resistant and others acquire resistance. In addition, toxicity to the peripheral nervous system can be problematic [2]. To address these limitations, a raft of second-generation antimitotic agents has been developed, including drugs targeting mitotic kinesins and mitotic kinases [3–7]. Effective clinical use of these novel agents will require the development of predictive biomarkers and patient stratification. This in turn will require an in-depth understanding of the molecular mechanisms by which these drugs kill cancer cells. At present, however, our understanding of the mechanisms by which mitotic dysfunction leads to cell death is still in its infancy.

Traditional antimitotic agents and many second-generation drugs are mitotic blockers [4]. By preventing spindle assembly, these drugs chronically activate the spindle assembly checkpoint leading to a prolonged mitotic arrest which eventually leads to cell death, either directly during mitosis or following slippage back into interphase [8]. Death in mitosis (DiM) and post-mitotic death (PMD) both result from activation of the intrinsic apoptotic machinery, which is regulated by pro-apoptotic and anti-apoptotic members of the Bcl-2 family [9–13]. On the pro-apoptotic side, the BH3-only proteins, Bim, Bid, Bad and Noxa, have been shown to contribute to death in mitosis [14–17]. On the anti-apoptotic side, Bcl-xL and Mcl-1 have been shown to be important mitotic survival factors [18–23]. However, the relative importance of any given Bcl-2 family member is complicated by two issues. First, there is considerable functional overlap among both the pro- and anti-apoptotic factors [12,24–26]. Second, whether these proteins act differently during DiM and PMD is often obscured by

population-based approaches that do not distinguish between death in mitosis or following slippage.

Understanding the relative contributions of the various Bcl-2 family members to mitotic cell fate is important from an antimitotic chemotherapy perspective because several pro-survival inhibitors are being evaluated as anti-cancer drugs [27,28]. For example, the BH3 mimetic compound class comprises several molecules that dock into a hydrophobic groove of pro-survival Bcl-2 family proteins, thereby preventing binding of their pro-apoptotic BH3-only partners [29]. Frontrunners in this class include ABT-737 and ABT-263/Navitoclax, related molecules that both inhibit three Bcl-2 family members, namely Bcl-2, Bcl-xL and Bcl-w. Notably, Navitoclax accelerates apoptosis during mitotic arrest induced by either taxol or inhibitors targeting the Eg5 kinesin [21]. In addition, exposing the slippage-prone MDA-MB-231 breast cancer cell line to ABT-737 induces death in mitosis [18]. In these cases, suppressing Bcl-xL using RNAi phenocopied the BH3 mimetic, indicating that Bcl-xL plays an important pro-survival role during a prolonged mitotic arrest.

More recently, novel BH3 mimetics have been developed with enhanced specificity for individual pro-survival Bcl-2 family members, including ABT-199 (which targets Bcl-2 itself) [30], A-1210477 (which targets Mcl-1) [31], and WEHI-539 [32] plus a related compound, A-1155643 [33], both of which target Bcl-xL. A-1155643 enhances the efficacy of docetaxel *in vitro* and in mouse xenograft models [31], further supporting the notion that Bcl-xL resists apoptosis during a prolonged mitotic arrest. However, we recently showed that WEHI-539 induces post-mitotic apoptosis when RKO cells are treated with a low concentration of taxol [12], indicating that Bcl-xL also supports survival following an abnormal mitosis. Therefore, to further explore the role of Bcl-xL in the context of mitotic perturbations, we set out to determine the relative contribution of Bcl-xL to survival following exposure to various antimitotic agents, including mitotic blockers and drivers [4,34]. Moreover, to determine Bcl-xL's role during a prolonged mitotic arrest, following slippage and following an abnormal mitosis, we used single-cell time-lapse imaging to directly correlate mitotic behavior with subsequent cell fate [8].

## 2. Results

### 2.1. Validation of WEHI-539 as an effective Bcl-xL inhibitor

WEHI-539 was recently described as a potent and selective Bcl-xL inhibitor [32]. As a BH3 mimetic, it docks into a hydrophobic groove of Bcl-xL, thereby blocking the binding of Bcl-xL's BH3-only partner proteins. To assess WEHI-539 as a research tool in our experimental systems, we first performed four validation experiments. For each we used RKO colon cancer cells in which there is substantial functional overlap between Bcl-xL and Mcl-1: while inhibition of either in isolation has little impact, inhibiting both is sufficient to induce apoptosis in the absence of cytotoxic insult [12] (see the electronic supplementary material, figure S1a). To measure apoptosis, we used time-lapse imaging and cell fate profiling in conjunction with a fluorescent caspase 3/7 reporter [8,12]. First, we reasoned that if WEHI-539 is selective for Bcl-xL over Mcl-1, then it should only induce

apoptosis in RKO cells in the absence of Mcl-1. Indeed, while WEHI-539 alone was relatively benign up to concentrations of 5  $\mu$ M (electronic supplementary material, figure S1a), following Mcl-1 RNAi, 100 nM was sufficient to induce extensive apoptosis (figure 1a; electronic supplementary material, figure S1a).


Bcl-xL sequesters multiple BH3-only proteins, including the apoptosis activator Bim which is involved in taxol sensitivity [12,35,36]. Secondly, therefore, we asked whether WEHI-539 exacerbated the ability of a tet-responsive Bim transgene to induce apoptosis (electronic supplementary material, figure S1b). Indeed, while induction of Bim with 30 ng ml<sup>-1</sup> tetracycline only induced moderate apoptosis, 100 nM WEHI-539 substantially enhanced the effect (figure 1b). Note that Bim overexpressing cells exposed to WEHI-539 typically died very shortly after mitosis (electronic supplementary material, figure S1b), an issue we return to in the Discussion.

Thirdly, we asked whether WEHI-539 blocked the binding of Bcl-xL to its partner BH3-only proteins. Indeed, when we affinity-purified GFP-tagged Bcl-xL in the presence of 100 nM WEHI-539, levels of co-purifying Bim, Bad, Bax and Bak were all reduced (figure 1c; electronic supplementary material, figure S1c). And finally, because overexpression of a tet-responsive Bcl-xL transgene potently resists taxol-induced apoptosis [12], we asked whether WEHI-539 reversed this effect. Indeed, while induction of Myc-tagged Bcl-xL with 100 ng ml<sup>-1</sup> tetracycline completely blocked taxol-induced apoptosis, this was reversed by 100 nM WEHI-539 (figure 1d; electronic supplementary material, figure S1d). Thus, these observations confirm that WEHI-539 behaves as one would expect for a potent and selective Bcl-xL inhibitor.

Because we previously showed that Bcl-xL overexpression resists apoptosis both in mitosis and following slippage [12], we were interested to determine whether the effect of WEHI-539 in the context of Bcl-xL overexpression was via restoration of DiM or PMD. Cell fate profiling showed that in the presence of taxol, 86% of RKO cells underwent DiM and only 14% slipped (figure 1e). Every cell that slipped then underwent PMD, with an average of 18.5 h between mitotic exit and death. Consistent with our prior observations [12], overexpression of Bcl-xL dramatically shifted the balance from DiM to slippage, with 94% undergoing slippage. Of these, only 6% underwent PMD, with an average onset time of 26 h. Interestingly, while 50 and 100 nM WEHI-539 only marginally reversed the balance back towards DiM, these concentrations had a major impact on PMD, increasing both the frequency and accelerating its onset (figure 1e). By contrast, 500 nM WEHI-539 completely shifted the balance back in favour of DiM. Thus, these observations confirm that Bcl-xL is a potent pro-survival factor both during a prolonged mitotic arrest and following slippage.

### 2.2. WEHI-539 sensitizes cells to microtubule-binding agents


Having validated WEHI-539 as a valuable research tool to probe Bcl-xL function in the context of mitotic cell fate, we set out to determine whether it sensitized cancer cells to various mitotic blockers, initially focusing on the microtubule-binding agents taxol and nocodazole. RKO cells were exposed to a matrix of increasing drug concentrations, then caspase 3/7



**Figure 1.** Validation of WEHI-539 as an effective Bcl-xL inhibitor. (a) Line graph showing apoptosis induction over a 72 h time course after RKO cells were transfected with siRNAs targeting Mcl-1 for 24 h before exposure to 100 nM WEHI-539. (b) Line graph showing apoptosis induction following expression of Bim with 30 ng ml<sup>-1</sup> tetracycline (Tet) and exposure to 100 nM WEHI-539. (c) Immunoblots showing affinity purification of GFP-tagged Bcl-xL induced with 100 ng ml<sup>-1</sup> tetracycline in the presence and absence of 100 nM WEHI-539, and detection of co-purifying Bim, Bad, Bak and Bax. Note that 100 nM WEHI-539 diminishes binding of pro-apoptotic proteins. (d) Line graph showing apoptosis induction by 100 nM taxol, suppression by the induction of Myc-tagged Bcl-xL, and restoration by 100 nM WEHI-539. (e) Cell fate profiles of RKO cells exposed to 100 nM taxol following induction of Myc-tagged Bcl-xL and exposure to increasing concentrations of WEHI-539. The number of cells undergoing death in mitosis (red), slippage (blue) and PMD (green) is quantitated in the bar graph. For the cells that undergo PMD, the scatter plot shows the time from mitotic exit to death. \**p* < 0.05. Zero hours on the fate profiles represents when cells entered mitosis.

activation measured by time-lapse imaging over a 72 h time course (figure 2a). As shown above, WEHI-539 alone was relatively benign but, as anticipated, taxol and nocodazole induced apoptosis in dose-dependent manners. Importantly, the matrix approach readily identified concentrations where the combination dramatically enhanced apoptosis. Specifically, while 10 nM taxol and 20 ng ml<sup>-1</sup> nocodazole only

induced apoptosis to 46% and 23% of the maximum, respectively, inclusion of 100 nM WEHI-539 induced near-maximal cell death (figure 2b). At these relatively low concentrations of antimetabolic drug, while many RKO cells underwent DiM, rather than slipping the remainder eventually completed cell division (figure 2c). In taxol, some of the dividers underwent PMD but in nocodazole they all arrested in the next



**Figure 2.** WEHI-539 sensitizes cells to microtubule-binding agents. (a) Concentration matrices showing apoptosis induction over a 72 h time course following exposure of RKO cells to either taxol or nocodazole and WEHI-539. (b) Line graphs showing apoptosis induction following exposure to 10 nM taxol or 20 ng ml<sup>-1</sup> nocodazole (Noc) plus 100 nM WEHI-539. (c) Cell fate profiles of cells as treated in (b). For those cells undergoing death in mitosis, the scatter plots quantitate the time from mitotic entry to cell death. #*p* < 0.0001. Zero hours on the fate profiles represents when cells entered mitosis.

interphase. Interestingly, the mechanism by which WEHI-539 enhanced apoptosis differed between the two mitotic blockers. In taxol, WEHI-539 had two effects, accelerating DiM by approximately 3.5 h and increasing the frequency of PMD

(figure 2c). By contrast, WEHI-539 did not accelerate DiM in nocodazole-treated cells but rather induced PMD in every cell that divided. Nevertheless, despite these differences, these observations build on prior reports [37], and



clearly demonstrate that pharmacological inhibition of Bcl-xL sensitizes cells to microtubule-binding agents.

### 2.3. WEHI-539 sensitizes cells to second-generation mitotic blockers

Like the microtubule-binding agents, several second-generation antimetabolic drugs also block mitotic progression by disrupting spindle assembly [3,4]. These include inhibitors targeting mitotic kinesins, such as Eg5 and Cenp-E, and mitotic kinases such as Plk1. We therefore asked whether pharmacological inhibition of Bcl-xL also sensitized cells to agents targeting these mitotic regulators, focusing on the Eg5 inhibitor AZ138 [8], the Plk1 inhibitor BI 2536 [38] and the Cenp-E inhibitor GSK923295 [39]. As above, RKO cells were analysed following exposure to a matrix of increasing drug concentrations, which again readily identified combinatorial concentrations that enhanced apoptosis (electronic supplementary material, figure S2a). To define this phenomenon in more detail, we performed cell fate profiling at concentrations where the enhancement of apoptosis was particularly marked.

In the case of the Eg5 inhibitor, sensitivity to 200 nM AZ138 was enhanced by 100 nM WEHI-539 (figure 3a). Note however that 1  $\mu$ M AZ138 is typically required to induce a potent mitotic block [8]. Indeed, at 200 nM, while 54% underwent DiM and 6% slipped, 40% eventually divided (figure 3b). As above with nocodazole, these dividers never entered another mitosis, suggesting cell cycle arrest. Notably, in the presence of 100 nM WEHI-539, 68% of the dividers underwent apoptosis (figure 3b). Thus, Bcl-xL inhibition sensitizes RKO cells to Eg5 inhibition by enhancing PMD rather than DiM. The ability of WEHI-539 to enhance apoptosis was particularly striking in the case of the Plk1 inhibitor BI 2536; whereas 50 nM alone only induced 21% apoptosis, 100 nM WEHI-539 increased this to 70% (figure 3a). As with nocodazole and the Eg5 inhibitor, WEHI-539 did not significantly accelerate the time to DiM but rather induced PMD following slippage or cell division (figure 3b,c). As above, at the relatively low concentration of 50 nM BI 2536, a substantial proportion of cells eventually divided (figure 3b). Therefore, we asked what happened at higher concentrations of BI 2536, which induced a potent cell division block. At 500 nM, the majority of cells underwent DiM or PMD after slippage (electronic supplementary material, figure S2b). Of those cells that slipped, 78% of cells underwent PMD after an average of 9.1 h (figure 3d). When 100 nM WEHI-539 was included, PMD was accelerated to 2.4 h (figure 3d; electronic supplementary material, figure S3b). Note that, paradoxically, at BI 2536 concentrations above 500 nM, apoptosis induction was reduced (electronic supplementary material, figure S2a), most probably due to suppression of mitotic entry [40]. Nevertheless, as with the Eg5 inhibitor, WEHI-539 sensitizes RKO cells to Plk1 inhibition largely by enhancing PMD. This phenomenon was strikingly apparent with the Cenp-E inhibitor. At 100 nM GSK923295, 66% of cells eventually divided, 21% of which then underwent PMD after an average of 12.6 h (figure 3b–d). Upon inclusion of 100 nM WEHI-539, 97% of the dividers underwent PMD after an average 3.6 h. Thus, together with the observations described above, these data demonstrate that inhibiting Bcl-xL can sensitize cells to second-generation mitotic blockers, largely by enhancing post-mitotic cell death.


### 2.4. WEHI-539 only has a minor impact when combined with mitotic drivers

In contrast to the microtubule-binding agents, several second-generation antimetabolic drugs do not trigger a prolonged mitotic arrest, but rather drive cells through an abnormal division [4]. These include drugs targeting Aurora A, Aurora B and Mps1. To determine whether inhibiting Bcl-xL also sensitized cells to these drugs, we analysed WEHI-539 in combination with the Aurora A inhibitor MLN8054 [41], the Aurora B inhibitor ZM447439 [42] and the Mps1 inhibitor AZ3146 [43]. In isolation, all three drugs induced the expected phenotypes; MLN8054 induced a transient mitotic delay followed by cell division, ZM447439 induced a transient delay followed by cytokinesis failure and AZ3146 accelerated mitotic exit (figure 4a,c). While inhibiting Aurora A or Aurora B alone was not sufficient to induce apoptosis, at least during the 72 h time course, the Mps1 inhibitor induced PMD in 38% of cells (figure 4c). Interestingly, the concentration matrices failed to identify combinations where WEHI-539 significantly enhanced apoptosis (not shown). Even at relatively high concentrations of mitotic driver, WEHI-539 had little additional effect especially in the case of the two Aurora kinase inhibitors (figure 4b,c). WEHI-539 did have a minor effect when combined with Mps1 inhibitor, increasing PMD to 62% and accelerating its onset by 4 h, although this latter difference was not statistically significant (data not shown). Thus, while pharmacological inhibition of Bcl-xL convincingly sensitizes cells to mitotic blockers, it only has a minor effect when combined with mitotic drivers.


To explore this notion further, we used the concentration matrices to perform a Bliss independence analysis [44,45], and represented the data as heat maps with positive Bliss excess values coloured green and negative values red (electronic supplementary material, figure S3). The heat maps for the microtubule toxins AZ138, BI 2536 and GSK923295 are characterized by patches of green (i.e. positive Bliss excess scores). By contrast, the heat maps for MLN8054, ZM447439 and AZ3146 are dominated by negative values, further supporting the notion that inhibiting Bcl-xL has little impact in the context of a mitotic driver. Accordingly, the mitotic blockers all returned high Bliss sum values, while MLN8054 and ZM447439 returned negative Bliss sums (electronic supplementary material, figure S3b). AZ3146 gave a positive albeit low Bliss sum, consistent with the observation that it enhances PMD to some extent (figure 4c). Thus, this analysis confirms the notion that while pharmacological inhibition of Bcl-xL sensitizes cells to mitotic blockers, this effect is considerably less pronounced when combined with mitotic drivers.

### 2.5. Overexpression of Mcl-1 suppresses WEHI-539-induced post-mitotic death

To rationalize the differential effect Bcl-xL inhibition had on mitotic blockers versus mitotic drivers, we turned our attention to Mcl-1, a pro-survival factor that is degraded during a prolonged mitotic arrest [46–49] (see the electronic supplementary material, figure S4b). We reasoned that if both Mcl-1 and Bcl-xL promote post-mitotic survival, then degradation of Mcl-1 during a prolonged mitotic arrest could account for why cells treated with mitotic blockers become




**Figure 3.** WEHI-539 sensitizes cells to second-generation mitotic blockers. (a) Line graphs showing apoptosis induction over a 72 h time course following exposure of RKO cells to 200 nM of the Eg5 inhibitor AZ138, 50 nM of the Plk1 inhibitor BI 2536, and 100 nM of the Cenp-E inhibitor GSK923295, plus 100 nM WEHI-539. (b) Cell fate profiles of cells treated as in (a). (c) Bar graph quantitation of (b) showing the number of cells undergoing each fate. (d) Scatter plot showing the time from mitotic exit to death for the cells that underwent PMD. Note that in the case of the Plk1 inhibitor, the data in panel (d) are derived from 500 nM BI 2536.  $^{\#}p < 0.0001$ . Zero hours on the fate profiles represents when cells entered mitosis.



**Figure 4.** WEHI-539 only has a minor impact when combined with mitotic drivers. (a) Scatter plot quantitating the time RKO cells spent in mitosis following exposure to 250 nM of the Aurora A inhibitor MLN8054, 2  $\mu$ M of the Aurora B inhibitor ZM447439 and 2  $\mu$ M of the Mps1 inhibitor AZ3146. \*\*\* $p$  < 0.01, # $p$  < 0.0001. (b) Line graphs showing apoptosis induction following exposure to the drugs indicated in (a) plus 100 nM WEHI-539. (c) Cell fate profiles of cells treated as in (b). Zero hours on the fate profiles represents when imaging started.

critically dependent on Bcl-xL. Indeed, while Mcl-1 was largely depleted during a nocodazole arrest, its levels remained high in the presence of ZM447439 (electronic supplementary material, figure S4b). Therefore, to test this hypothesis further, we modulated Mcl-1 levels in RKO cells and asked whether this altered their sensitivity to combinations of antimetabolic agents plus WEHI-539.

First, we generated an RKO cell line expressing a tet-inducible GFP-tagged Mcl-1 transgene in order to overexpress Mcl-1 (electronic supplementary material, figure S4a). When uninduced control cells were exposed to 20 ng ml<sup>-1</sup> of nocodazole, the vast majority of cells arrested for an average of 4 h then divided (figure 5a). Of these, only 17% underwent PMD after an average of 32 h. Consistent with observations shown



**Figure 5.** Inhibition of Mcl-1 sensitizes WEHI-539-treated cells to a mitotic driver. (a) Cell fate profiles of RKO cells treated with 20 ng ml<sup>-1</sup> nocodazole and 100 nM WEHI-539 following induction of GFP-tagged Mcl-1 with 1  $\mu$ g ml<sup>-1</sup> tetracycline (Tet). (b) Scatter plot showing the time from mitotic exit to death for WEHI-539-treated cells in (a) that underwent PMD in the presence or the absence of overexpressed Mcl-1. # $p < 0.0001$ . (c) Cell fate profiles of RKO cells exposed to 2  $\mu$ M of the Aurora B inhibitor ZM447439, 100 nM WEHI-539 and 2  $\mu$ M of the Mcl-1 inhibitor A-1210477. (d) Bar graph quantitation of (c) showing the number of cells undergoing each fate, and scatter plot quantitating the time from mitotic exit to death for the cells that underwent PMD. # $p < 0.0001$ . (e) Cell fate profiles of DLD-1 cells exposed to 2  $\mu$ M ZM447439 and 100 nM WEHI-539. (f) Bar graph quantitation of (e) showing the number of cells undergoing each fate. In panel (a), zero hours on the fate profiles represents when cells entered mitosis, while in panels (c) and (e) it corresponds to when imaging started.



in figure 2c, 100 nM WEHI-539 induced rapid PMD in the vast majority of dividers (figure 5a). Overexpression of Mcl-1 only had a minor impact in the absence of WEHI-539, prolonging time to death in the few cells that underwent DiM. However, Mcl-1 overexpression had a significant impact in the presence of WEHI-539, substantially prolonging the onset of PMD in a subset of the cells, extending the average time to PMD from 2.8 to 17.5 h (figure 5b). Thus, elevating Mcl-1 suppresses post-mitotic sensitivity to WEHI-539, consistent with the notion that a prolonged mitotic arrest sensitizes cells to Bcl-xL inhibitors by degrading Mcl-1.

## 2.6. Inhibition of Mcl-1 sensitizes cells to WEHI-539 plus an Aurora B inhibitor

Next, we suppressed Mcl-1 by RNAi and asked whether this sensitized Bcl-xL-inhibited cells to a mitotic driver. Consistent with the data in figure 4c, adding WEHI-539 to the Aurora B inhibitor ZM447439 had little effect. However, when Mcl-1 was suppressed by RNAi, apoptosis was induced in the majority of cells, either during mitosis or following cell division failure (electronic supplementary material, figure S4c). However, this experiment is complicated because co-inhibition of Mcl-1 and Bcl-xL in RKO cells is sufficient to induce apoptosis even in the absence of extrinsic insult [12] (see the electronic supplementary material, figure S1a). Indeed, despite reducing the concentration of siRNAs targeting Mcl-1 to 25 nM, when combined with 100 nM WEHI-539, the vast majority of cells died, either in mitosis or shortly thereafter (electronic supplementary material, figure S4c). In fact, the addition of the Aurora B inhibitor actually conferred protection, reducing the number of cells dying in mitosis and delaying PMD, possibly due to suppressing telomere deprotection [12,50] (see Discussion). Therefore, to enable better titration of Mcl-1 function, rather than RNAi we turned to the Mcl-1 inhibitor, A-1210477 [31]. Like WEHI-539, A-1210477 is a BH3-mimetic and inhibits Mcl-1 from binding its pro-apoptotic partners (electronic supplementary material, figure S4d). First, we analysed a concentration matrix to identify a combinatorial concentration of WEHI-539 and A-1210477 that induced minimal apoptosis (electronic supplementary material, figure S4e). When used in isolation, 100 nM WEHI-539 and 2  $\mu$ M A-1210477 did not suppress proliferation or induce apoptosis, and in combination only had a minor effect (electronic supplementary material, figure S4e). Cell fate profiling confirmed that 2  $\mu$ M A-1210477 in isolation or in combination with ZM447393 had little effect (figure 5c). When combined with WEHI-539, 2  $\mu$ M A-1210477 induced apoptosis in 44% of cells. However, addition of ZM447439 greatly enhanced this, increasing the apoptotic fraction to 86% and accelerating the average time from mitotic exit to death from 35 h to 10 h (figure 5c,d). Thus, despite the technical difficulties inherent when suppressing both Mcl-1 and Bcl-xL, these observations show that Mcl-1 promotes post-mitotic survival when Bcl-xL-inhibited cells are driven through an abnormal division. In turn, this supports the hypothesis that RKO cells become dependent on Bcl-xL function after exiting a protracted mitosis due to degradation of Mcl-1 during the delay.

## 2.7. Mcl-1-deficient DLD-1 cells are sensitive to WEHI-539 when combined with ZM447439

If both Mcl-1 and Bcl-xL support post-mitotic survival when cells are exposed to mitotic drivers, then we reasoned that cell lines already deficient for Mcl-1 should be sensitive to the combination of a Bcl-xL inhibitor plus a mitotic driver. To test this, we turned to DLD-1 cells, another colon cancer cell line which, compared with RKO, has a relatively lower level of Mcl-1 [49]. In contrast to RKO, exposing DLD-1 cells to WEHI-539 and ZM447439 separately was sufficient to induce apoptosis in a fraction of cells (figure 5e,f), consistent with weakened Mcl-1 function. More importantly, however, combining WEHI-539 with ZM447439 induced PMD in 76% of cells. Thus, in a cell line lacking robust Mcl-1 function, post-mitotic survival in the presence of a mitotic driver is dependent on Bcl-xL function.

## 3. Discussion

Bcl-xL has previously been implicated as an important mitotic survival factor [12,18,20–22]. To further refine our understanding of Bcl-xL's role when mitosis is disrupted, we have taken advantage of WEHI-539, a BH3 mimetic that selectively and potently blocks binding of Bcl-xL to its BH3-only pro-apoptotic partner proteins [32]. Using concentration matrices to combine WEHI-539 with a panel of representative antimitotic agents, we have systematically analysed Bcl-xL's pro-survival potential in response to drugs that either block or accelerate mitotic progression. In addition, by using cell fate profiling we were able to differentiate death in mitosis from post-mitotic apoptosis. Our results demonstrate that Bcl-xL sustains survival following perturbations that induce a prolonged mitotic delay. By contrast, Bcl-xL function is less critical when cells are driven through an abnormal mitosis, most probably due to the compensatory action of Mcl-1.

### 3.1. Both Bcl-xL and Mcl-1 promote survival following an aberrant mitosis

During mitosis, transcription and translation are heavily suppressed. Indeed, the regulation of mitotic progression is governed largely by post-translational modifications, in particular protein phosphorylation and ubiquitin-mediated proteolysis [51–53]. Accordingly, the apoptotic proteome is also extensively modified during mitosis; for example, Caspase-9, Bid and Bcl-xL are phosphorylated by mitotic kinases [16,22,54–56]. Pro-apoptotic Bim is ubiquitinated by the anaphase-promoting complex (APC/C), the E3 ubiquitin ligase that also targets Cyclin B1 for degradation [15]. However, the net physiological effect these post-translational modifications have on the apoptotic threshold is unclear. Moreover, how these modifications change during a delayed or abnormal mitosis is also not clear. An exception is pro-survival Mcl-1, with several independent reports showing that it is slowly degraded during a checkpoint-mediated mitotic arrest [46,48,49]. Mcl-1 degradation is proteasome dependent and while several E3 ligases have been implicated, the exact mechanism remains to be delineated [49,57]. Nevertheless, several independent observations support the notion that Mcl-1 degradation serves as a mitotic 'death timer'

mechanism [14,58]. For example, we recently showed that when mitotic exit is blocked in RKO cells by expression of a non-degradable Cyclin B1 mutant, Mcl-1 RNAi accelerates DiM [49]. Conversely, overexpressing Mcl-1 delays taxol-induced DiM by over 5 h. Modulating Mcl-1 also influences post-mitotic survival. We recently showed that Mcl-1 RNAi in slippage-prone DLD-1 cells increases the frequency of apoptosis after slippage, while overexpressing it delays PMD [49]. Taken together with the functional overlap between Mcl-1 and Bcl-xL [12,24,25], these observations allowed us to formulate a simple hypothesis to account for why pharmacological inhibition of Bcl-xL sensitized cells to mitotic blockers but not mitotic drivers, namely that degradation of Mcl-1 during the prolonged delay induced by a blocker renders cells more dependent on Bcl-xL when they eventually exit mitosis. Our subsequent experiment showing that simultaneous inhibition of Bcl-xL and Mcl-1 accelerates PMD in response to an Aurora B inhibitor supports this hypothesis. In turn, this further supports the notion that both Bcl-xL and Mcl-1 contribute to survival following an aberrant mitosis.

### 3.2. In the absence of robust pro-survival activity, mitosis induces apoptosis

Consistent with their overlapping function, simultaneous inhibition of Bcl-xL and Mcl-1 can induce apoptosis even in the absence of cytotoxic insult. This has been shown previously by others [24], but we noted recently that co-repression of Bcl-xL and Mcl-1 by RNAi causes RKO cells to die either in mitosis or very shortly following mitotic exit [12]. Here, we made a similar observation: in the absence of any additional exogenous stress, Mcl-1 RNAi cells exposed to WEHI-539 died either in mitosis or very shortly after mitotic exit. This does not appear to be an RNAi-related phenomenon; when both Bcl-xL and Mcl-1 were inhibited pharmacologically, using WEHI-539 and A-1210477, apoptosis occurred frequently in mitosis or shortly thereafter (not shown). Moreover, when cells overexpressing Bim were exposed to WEHI-539, the vast majority of cells died shortly after completing mitosis. These observations indicate that in the absence of adequate pro-survival activity, mitosis itself is sufficiently stressful to cause apoptosis. One possible trigger for mitosis-specific stress is telomere deprotection, a phenomenon whereby mitotic Aurora B kinase activity displaces TRF2 from telomeres, giving rise to an exposed telomere that is recognized by DNA damage response pathways [50,59]. Consistent with this notion, we previously showed that overexpression of TRF2 or inhibition of Aurora B suppresses mitotic apoptosis in Bcl-xL/Mcl-1-deficient cells [12]. Here, we confirm this in that inhibition of Aurora B delayed apoptosis in Mcl-1RNAi cells exposed to WEHI-539. However, whether telomere deprotection is sufficient to account for apoptosis in cells with weakened pro-survival function remains to be seen. Indeed, this is a very intriguing phenomenon that warrants further investigation. Interestingly, a prolonged mitotic arrest results in mitophagy, reduction in ATP levels and activation of AMPK, and a metabolic switch from oxidative respiration to glycolysis [11]. One possibility therefore is that mitosis-dependent changes in metabolism and/or mitochondrial function could also contribute to mitotic stress that is sufficient

to induce apoptosis in cells with weakened pro-survival function.

### 3.3. Identification of patients likely to benefit from antimitotic/Bcl-xL inhibitor combinations

The taxanes and other antimitotic agents are vitally important chemotherapy agents. Yet exactly how they yield patient benefit remains obscure. Recently, the Mps1 inhibitor NTRC 0066-0 was shown to potentiate the anti-tumour activity of docetaxel in a mouse model of triple-negative breast cancer [60]. Strikingly, however, the Mps1 inhibitor alone had little effect, strongly suggesting that docetaxel's anti-tumour activity is via a mitotic mechanism. Indeed, an analysis of breast cancer biopsies indicates that tumour responses correlate with abnormal mitoses observed shortly after taxol infusion [61]. Here, we show that Bcl-xL is a potent pro-survival factor in this context: over a range of clinically relevant taxol concentrations, WEHI-539 enhanced apoptosis by both accelerating death in mitosis and by elevating the frequency of apoptosis following an abnormal mitosis. These observations support and extend previous reports showing that Navitoclax enhances cell death in response to antimitotic agents [18,21,37,62,63]. Together, these observations make a compelling case for exploring Bcl-xL inhibitors in combination with taxanes in order to enhance antimitotic chemotherapy. However, such combinations will inevitably come with an increased toxicity profile. Indeed, Bcl-xL is a molecular clock in platelets, defining their lifespan [64,65]. Consequently, Bcl-xL inhibitors induce thrombocytopenia [66,67], and while this can be ameliorated clinically, judicious use will be required to open up a useful therapeutic window. Interestingly, ovarian cancers with relatively high Bcl-xL levels are less responsive to taxane-based therapy, and ovarian cancer cell lines with higher Bcl-xL/Mcl-1 ratios showed higher Bliss sum values when treated with Navitoclax and taxol [45]. Taken together with our observations, this suggests that patients whose tumours have high Bcl-xL/Mcl-1 ratios might be good candidates for Bcl-xL inhibitor trials in combination with antimitotic agents. Similarly, early-phase clinical trials evaluating novel mitotic blockers (e.g. those targeting Plk1 and Cenp-E) might also benefit by pre-selecting patients with high Bcl-xL/Mcl-1 ratios and exploring combinations with Bcl-xL inhibitors. Conversely, exploring Bcl-xL inhibitors may be less promising in the context of mitotic drivers unless patients whose tumours have low Mcl-1 levels can be identified.

## 4. Material and methods

### 4.1. Cell lines

Parental RKO and DLD-1 cells, plus RKO Flp-In T-Rex derivatives expressing Bim, Myc-tagged Bcl-xL and GFP-tagged Mcl-1, were as described [12,49,68]. All lines were cultured in DMEM plus 10% fetal calf serum (Life Technologies), 100 U ml<sup>-1</sup> penicillin, 100 U ml<sup>-1</sup> streptomycin and 2 mM glutamine (all from Sigma), then maintained at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. A stable RKO line harbouring a tetracycline-inducible GFP-tagged Bcl-xL was generated as described [69]. In brief, a Bcl-xL cDNA [12]

was cloned into a pcDNA5/FRT/TO-based vector (Invitrogen) then co-transfected with pOG44 into Flp-In T-Rex RKO cells using Lipofectamine Plus (ThermoFisher). Stable integrants were selected in 400  $\mu\text{g ml}^{-1}$  hygromycin B (Roche) and 8  $\mu\text{g ml}^{-1}$  blasticidin (Melford), colonies pooled and expanded to create an isogenic population. To synchronize cells in S-phase, cells were treated with 2 mM thymidine for 16 h.

## 4.2. Small molecule inhibitors

The following drugs were dissolved in DMSO and stored at  $-20^{\circ}\text{C}$ : WEHI-539 [32] (Apexbio); taxol (Sigma); nocodazole (Sigma); AZ138 [8] (AstraZeneca); AZ3146 [43] (AstraZeneca); BI 2536 [38] (Boehringer Ingelheim); GSK923295 [39,70]; MLN8054 [41] (Millennium Pharmaceuticals); ZM447439 [42] (Tocris); A-1210477 [31] (Medchemexpress). Tetracycline (Sigma) was dissolved in water, stored at  $-20^{\circ}\text{C}$ , and used at concentrations indicated in the figure legends. Thymidine (Sigma) was dissolved in PBS at a concentration of 200 mM, and stored short-term at  $4^{\circ}\text{C}$ .

## 4.3. RNAi

For RNAi-mediated inhibition, cells were plated in  $\mu\text{clear}^{\text{®}}$  96-well plates (Greiner Bio-One) then transfected with a final concentration of 66 nM siRNA using DharmaFECT 1 transfection reagent (Dharmacon) in Opti-MEM media (Life Technologies). siRNAs were ON-TARGETplus SMARTpools (Dharmacon) as described [12] containing oligonucleotides with the following sequences: Bcl-xL (5'-GGACAGCAUAUCAGAGCUU-3', 5'-GAAAUGACCAGACACUGAC-3', 5'-CCUACAAGCUUCCCCAGAA-3', 5'-UUAGUGAUGUGGAAGAGAA-3'), Mcl-1 (5'-CGAAGGAAGUAUCGAAUUU-3', 5'-GAUUAUCUCUCGGUACCUU-3', 5'-GAAGGUGGCAUCAGGAAUG-3', 5'-GGUUUGCAUAUCUAAUAA-3'), non-targeting control (5'-UGGUUUACAUGUCGACUAA-3', 5'-UGGUUUACAUGUUGUGUGA-3', 5'-GGUUUACAUGUUUUCUGA-3', 5'-UGGUUUACAUGUUUCCUA-3').

## 4.4. Proliferation and apoptosis assays

To measure apoptosis induction and proliferation and to perform cell fate profiling,  $1 \times 10^5$  cells were seeded per well in  $\mu\text{clear}$  96-well plates (Greiner Bio-One) and IncuCyte Kinetic Caspase-3/7 Apoptosis Assay Reagent (Essen BioScience) added. Note that this cell-permeable reagent consists of a caspase-3/7 recognition motif (DEVD) coupled to a DNA intercalating dye. Upon cleavage by activated caspase-3/7, the liberated dye binds nuclear DNA and emits green fluorescence [71]. Fluorescence values were then normalized to control wells on the same plate which exhibited maximum apoptosis yielding percentage apoptosis values which were plotted. Note also that to maximize fluorescence detection, DMEM was replaced with Leibovitz's L-15 (Sigma-Aldrich). Cells were then imaged using an IncuCyte ZOOM (Essen BioScience) equipped with a  $20\times$  objective and maintained at  $37^{\circ}\text{C}$  in a humidified 5%  $\text{CO}_2$  atmosphere. Phase contrast and fluorescence images with two to four images per well were collected every 10–30 min and IncuCyte ZOOM software used in real-time to measure confluency, as a proxy for proliferation, and apoptosis, respectively. Image sequences were then exported in MPEG-4 format and

analysed manually to generate cell fate profiles [8]. IncuCyte ZOOM data and timing data were imported into PRISM 6 (GraphPad) for statistical analysis and presentation. Note that zero hours on the fate profiles represent either when cells entered mitosis or when imaging was started; see individual figure legends for details.

## 4.5. Immunoprecipitation

Flp-In T-Rex RKO cells harbouring an inducible GFP-tagged Bcl-xL transgene were seeded in 6-well plates and 100  $\text{ng ml}^{-1}$  tetracycline added overnight.  $10 \times 10^5$  cells were then harvested and lysed in 1 ml of buffer containing 0.1% Triton X-100, 100 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 20 mM  $\beta$ -glycerophosphate, 10 mM NaF and protease/phosphatase inhibitors (Roche). The lysate was then clarified by centrifugation at 16 000g for 20 min at  $4^{\circ}\text{C}$ . To 1 ml of supernatant, 30  $\mu\text{g}$  of a GST-GFP-nanotrap fusion protein was added [49,72] along with glutathione sepharose beads (Amintra). After incubation at  $4^{\circ}\text{C}$  with rotation for 2 h, beads were harvested by centrifugation and washed five times with lysis buffer. Bound proteins were eluted by boiling in sample buffer (0.35 M Tris pH 6.8, 0.1 g  $\text{ml}^{-1}$  sodium dodecyl sulfate, 93  $\text{mg ml}^{-1}$  dithiothreitol, 30% glycerol, 50  $\mu\text{g ml}^{-1}$  bromophenol blue) then resolved by SDS-PAGE.

## 4.6. Immunoblotting

Following SDS-PAGE, proteins were electroblotted onto Immobilon-P membranes. Following blocking in 5% dried skimmed milk (Marvel) dissolved in TBST (50 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20), membranes were incubated overnight at  $4^{\circ}\text{C}$  with the following primary antibodies diluted in TBST: 54H6 (Rabbit anti-Bcl-xL, 1:1000; Cell Signalling Technology), S-19 (Rabbit anti-Mcl-1, Santa Cruz Biotechnology), sheep anti-Tao1 (1:3000 [73]), rabbit anti-Bim (1:500; BD Biosciences), mouse anti-Bad (1:1000; Santa Cruz), rabbit anti-Bid (1:1000; Cell Signalling), mouse anti-Bax (1:1000; BD BioSciences), mouse anti-Bak (1:1000; Calbiochem), 4A6 (mouse anti-Myc tag; 1:1000; Millipore) and GFP (Rabbit anti-GFP; 1:1000; Cell Signalling). Membranes were then washed three times in TBST and incubated for at least 1 h with appropriate horseradish-peroxidase-conjugated secondary antibodies (Zymed). After washing in TBST, bound secondary antibodies were detected using either EZ-ECL Chemiluminescence Reagent (Biological Industries) or Luminata Forte Western HRP Substrate (Millipore) and a Biospectrum 500 imaging system (UVP).

## 4.7. Statistical methods and Bliss independence analysis

PRISM v. 6 (GraphPad) was used for statistical analysis, with non-parametric Mann–Whitney  $U$ -tests for all figures, where  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $^{\#}p < 0.0001$ , n.s.:  $p > 0.05$ . Lines on scatterplots show mean and interquartile ranges. Combination synergy of WEHI-539 with antimetabolic agents was determined by Bliss independence analyses [44,45]. A Bliss expectation for a combined response ( $C$ ) was calculated by the equation:  $C = (A + B) - (A \times B)$ , where  $A$  and  $B$  are the percentage apoptosis induced by drug  $A$  and  $B$  at a given dose. The difference between the Bliss expectation and the extent of apoptosis observed is the



Bliss excess. Bliss excess scores were then summed across the dose matrix to generate a Bliss sum, where a value equal to zero indicates that the combination is additive, a value greater than zero indicates synergy, while a Bliss sum of less than zero indicates antagonism.

**Data accessibility.** Research materials are available upon request to S.S.T.

**Authors' contributions.** The project was conceived by S.S.T. and A.B. A.B. performed all the experiments with the exception of S4D which was performed by O.S. O.S., C.T., L.N. and A.T. contributed key reagents.

A.B. and S.S.T. prepared the manuscript. All co-authors read and commented on the manuscript.

**Competing interests.** We declare we have no competing interests.

**Funding.** A.B. is funded by a studentship from Cancer Research UK and a University of Manchester Presidential Scholarship. O.S. and C.T. were supported by the Wellcome Trust and the Medical Research Council (MR/L006839/1), respectively. L.N., A.T. and S.S.T. are supported by Cancer Research UK.

**Acknowledgements.** We thank members of the Taylor lab for advice and comments on the manuscript.

## References

- Dumontet C, Jordan MA. 2010 Microtubule-binding agents: a dynamic field of cancer therapeutics. *Nat. Rev. Drug Discov.* **9**, 790–803. (doi:10.1038/nrd3253)
- Rowinsky EK. 1993 Clinical pharmacology of Taxol. *J. Natl. Cancer Inst. Monogr.* **15**, 25–37.
- Jackson JR, Patrick DR, Dar MM, Huang PS. 2007 Targeted anti-mitotic therapies: can we improve on tubulin agents? *Nat. Rev. Cancer* **7**, 107–117. (doi:10.1038/nrc2049)
- Keen N, Taylor S. 2009 Mitotic drivers—inhibitors of the Aurora B kinase. *Cancer Metastasis Rev.* **28**, 185–195. (doi:10.1007/s10555-009-9184-9)
- Taylor S, Peters JM. 2008 Polo and Aurora kinases: lessons derived from chemical biology. *Curr. Opin. Cell Biol.* **20**, 77–84. (doi:10.1016/j.ccb.2007.11.008)
- Lens SM, Voest EE, Medema RH. 2010 Shared and separate functions of polo-like kinases and aurora kinases in cancer. *Nat. Rev. Cancer* **10**, 825–841. (doi:10.1038/nrc2964)
- Malumbres M. 2011 Physiological relevance of cell cycle kinases. *Physiol. Rev.* **91**, 973–1007. (doi:10.1152/physrev.00025.2010)
- Gascoigne KE, Taylor SS. 2008 Cancer cells display profound intra- and interline variation following prolonged exposure to antimetabolic drugs. *Cancer Cell.* **14**, 111–122. (doi:10.1016/j.ccr.2008.07.002)
- Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. 2010 The BCL-2 family reunion. *Mol. Cell.* **37**, 299–310. (doi:10.1016/j.molcel.2010.01.025)
- Delbridge AR, Grabow S, Strasser A, Vaux DL. 2016 Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. *Nat. Rev. Cancer* **16**, 99–109. (doi:10.1038/nrc.2015.17)
- Domenech E *et al.* 2015 AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. *Nat. Cell Biol.* **17**, 1304–1316. (doi:10.1038/ncb3231)
- Topham C *et al.* 2015 MYC is a major determinant of mitotic cell fate. *Cancer Cell* **28**, 129–140. (doi:10.1016/j.ccell.2015.06.001)
- Topham CH, Taylor SS. 2013 Mitosis and apoptosis: how is the balance set? *Curr. Opin. Cell Biol.* **25**, 780–785. (doi:10.1016/j.ccb.2013.07.003)
- Haschka MD, Soratroi C, Kirschnek S, Hacker G, Hilbe R, Geley S, Villunger A, Fava LL. 2015 The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest. *Nat. Commun.* **6**, 6891. (doi:10.1038/ncomms7891)
- Wan L *et al.* 2014 APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. *Dev. Cell* **29**, 377–391. (doi:10.1016/j.devcel.2014.04.022)
- Wang P, Lindsay J, Owens TW, Mularczyk EJ, Warwood S, Foster F, Streuli CH, Brennan K, Gilmore AP. 2014 Phosphorylation of the proapoptotic BH3-only protein bid primes mitochondria for apoptosis during mitotic arrest. *Cell Rep.* **7**, 661–671. (doi:10.1016/j.celrep.2014.03.050)
- Diaz-Martinez LA, Karamysheva ZN, Warrington R, Li B, Wei S, Xie XJ, Roth MG, Yu H. 2014 Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation. *EMBO J.* **33**, 1960–1976. (doi:10.15252/embj.201487826)
- Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barille-Nion S. 2014 Bcl-xL controls a switch between cell death modes during mitotic arrest. *Cell Death Dis.* **5**, e1291. (doi:10.1038/cddis.2014.251)
- Chu R, Terrano DT, Chambers TC. 2012 Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. *Biochem. Pharmacol.* **83**, 199–206. (doi:10.1016/j.bcp.2011.10.008)
- Minn AJ, Boise LH, Thompson CB. 1996 Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. *Genes Dev.* **10**, 2621–2631. (doi:10.1101/gad.10.20.2621)
- Shi J, Zhou Y, Huang HC, Mitchison TJ. 2011 Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. *Cancer Res.* **71**, 4518–4526. (doi:10.1158/0008-5472.CAN-10-4336)
- Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, Chambers TC. 2008 Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. *J. Biol. Chem.* **283**, 35 517–35 525. (doi:10.1074/jbc.M805019200)
- Kawabata T, Tanimura S, Asai K, Kawasaki R, Matsumaru Y, Kohno M. 2012 Up-regulation of proapoptotic protein Bim and down-regulation of antiapoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor. *J. Biol. Chem.* **287**, 10 289–10 300. (doi:10.1074/jbc.M111.319426)
- Eichhorn JM, Alford SE, Sakurikar N, Chambers TC. 2014 Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. *Exp. Cell Res.* **322**, 415–424. (doi:10.1016/j.yexcr.2014.02.010)
- Eno CO, Zhao G, Olberding KE, Li C. 2012 The Bcl-2 proteins Noxa and Bcl-xL co-ordinately regulate oxidative stress-induced apoptosis. *Biochem. J.* **444**, 69–78. (doi:10.1042/BJ20112023)
- Wei MC *et al.* 2001 Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* **292**, 727–730. (doi:10.1126/science.1059108)
- Delbridge AR, Strasser A. 2015 The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ.* **22**, 1071–1080. (doi:10.1038/cdd.2015.50)
- Levenson JD. 2016 Chemical parsing: dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors. *Mol. Cell Oncol.* **3**, e1050155. (doi:10.1080/23723556.2015.1050155)
- Billard C. 2013 BH3 mimetics: status of the field and new developments. *Mol. Cancer Ther.* **12**, 1691–1700. (doi:10.1158/1535-7163.MCT-13-0058)
- Souers AJ *et al.* 2013 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat. Med.* **19**, 202–208. (doi:10.1038/nm.3048)
- Levenson JD *et al.* 2015 Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). *Cell Death Dis.* **6**, e1590. (doi:10.1038/cddis.2014.561)
- Lessene G *et al.* 2013 Structure-guided design of a selective BCL-X(L) inhibitor. *Nat. Chem. Biol.* **9**, 390–397. (doi:10.1038/nchembio.1246)
- Tao ZF *et al.* 2014 Discovery of a potent and selective BCL-XL inhibitor with *in vivo* activity. *ACS Med. Chem. Lett.* **5**, 1088–1093. (doi:10.1021/ml5001867)
- Manchado E, Guillamot M, Malumbres M. 2012 Killing cells by targeting mitosis. *Cell Death Differ.* **19**, 369–377. (doi:10.1038/cdd.2011.197)
- Kutuk O, Letai A. 2010 Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. *Cell Death Differ.* **17**, 1624–1635. (doi:10.1038/cdd.2010.41)

36. Li R, Moudgil T, Ross HJ, Hu HM. 2005 Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. *Cell Death Differ.* **12**, 292–303. (doi:10.1038/sj.cdd.4401554)
37. Levenson JD *et al.* 2015 Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. *Sci. Transl. Med.* **7**, 279ra240. (doi:10.1126/scitranslmed.aaa4642)
38. Steegmaier M *et al.* 2007 BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth *in vivo*. *Curr. Biol.* **17**, 316–322. (doi:10.1016/j.cub.2006.12.037)
39. Wood KW *et al.* 2010 Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. *Proc. Natl Acad. Sci. USA* **107**, 5839–5844. (doi:10.1073/pnas.0915068107)
40. 'Aspinall CF, Zheleva D, Tighe A, Taylor SS. 2015 Mitotic entry: non-genetic heterogeneity exposes the requirement for Plk1. *Oncotarget* **6**, 36 472–36 488. (doi:10.18632/oncotarget.5507)
41. Manfredi MG *et al.* 2007 Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. *Proc. Natl Acad. Sci. USA* **104**, 4106–4111. (doi:10.1073/pnas.0608798104)
42. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS. 2003 Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. *J. Cell Biol.* **161**, 267–280. (doi:10.1083/jcb.200208091)
43. Hewitt L, Tighe A, Santaguida S, White AM, Jones CD, Musacchio A, Green S, Taylor SS. 2010 Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. *J. Cell Biol.* **190**, 25–34. (doi:10.1083/jcb.201002133)
44. Lehar J *et al.* 2009 Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nat. Biotechnol.* **27**, 659–666. (doi:10.1038/nbt.1549)
45. Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD. 2012 Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. *Mol. Cancer Ther.* **11**, 1026–1035. (doi:10.1158/1535-7163.MCT-11-0693)
46. Harley ME, Allan LA, Sanderson HS, Clarke PR. 2010 Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. *EMBO J.* **29**, 2407–2420. (doi:10.1038/emboj.2010.112)
47. Millman SE, Pagano M. 2011 MCL1 meets its end during mitotic arrest. *EMBO Rep.* **12**, 384–385. (doi:10.1038/embor.2011.62)
48. Wertz IE *et al.* 2011 Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. *Nature* **471**, 110–114. (doi:10.1038/nature09779)
49. Sloss O, Topham C, Diez M, Taylor S. 2016 Mcl-1 dynamics influence mitotic slippage and death in mitosis. *Oncotarget* **7**, 5176–5192. (doi:10.18632/oncotarget.6894)
50. Hayashi MT, Cesare AJ, Fitzpatrick JA, Lazzarini-Denchi E, Karlseder J. 2012 A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. *Nat. Struct. Mol. Biol.* **19**, 387–394. (doi:10.1038/nsmb.2245)
51. Pines J. 2006 Mitosis: a matter of getting rid of the right protein at the right time. *Trends Cell Biol.* **16**, 55–63. (doi:10.1016/j.tcb.2005.11.006)
52. Nigg EA. 2001 Mitotic kinases as regulators of cell division and its checkpoints. *Nat. Rev. Mol. Cell Biol.* **2**, 21–32. (doi:10.1038/35048096)
53. Barr FA, Elliott PR, Gruneberg U. 2011 Protein phosphatases and the regulation of mitosis. *J. Cell Sci.* **124**, 2323–2334. (doi:10.1242/jcs.087106)
54. Allan LA, Clarke PR. 2007 Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. *Mol. Cell.* **26**, 301–310. (doi:10.1016/j.molcel.2007.03.019)
55. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T. 1998 Bcl-xL is phosphorylated in malignant cells following microtubule disruption. *Cancer Res.* **58**, 3331–3338.
56. Sakurikar N, Eichhorn JM, Chambers TC. 2012 Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. *J. Biol. Chem.* **287**, 39 193–39 204. (doi:10.1074/jbc.M112.391854)
57. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. 2010 Ubiquitin-independent degradation of antiapoptotic MCL-1. *Mol. Cell Biol.* **30**, 3099–3110. (doi:10.1128/MCB.01266-09)
58. Tunquist BJ, Woessner RD, Walker DH. 2010 Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. *Mol. Cancer Ther.* **9**, 2046–2056. (doi:10.1158/1535-7163.MCT-10-0033)
59. Colin DJ, Hain KO, Allan LA, Clarke PR. 2015 Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. *Open Biol.* **5**, 140156. (doi:10.1098/rsob.140156)
60. Maia AR *et al.* 2015 Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. *Ann. Oncol.* **26**, 2180–2192. (doi:10.1093/annonc/mdv293)
61. Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA. 2014 Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. *Sci. Transl. Med.* **6**, 229ra243. (doi:10.1126/scitranslmed.3007965)
62. Tan N, Malek M, Zha J, Yue P, Kassee R, Berry L, Fairbrother WJ, Sampath D, Belmont LD. 2011 Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. *Clin. Cancer Res.* **17**, 1394–1404. (doi:10.1158/1078-0432.CCR-10-2353)
63. Chen J *et al.* 2011 The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents *in vitro* and *in vivo*. *Mol. Cancer Ther.* **10**, 2340–2349. (doi:10.1158/1535-7163.MCT-11-0415)
64. Mason KD *et al.* 2007 Programmed anuclear cell death delimits platelet life span. *Cell* **128**, 1173–1186. (doi:10.1016/j.cell.2007.01.037)
65. Zhang H *et al.* 2007 Bcl-2 family proteins are essential for platelet survival. *Cell Death Differ.* **14**, 943–951. (doi:10.1038/sj.cdd.4402081)
66. Roberts AW *et al.* 2012 Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *J. Clin. Oncol.* **30**, 488–496. (doi:10.1200/JCO.2011.34.7898)
67. Tse C *et al.* 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* **68**, 3421–3428. (doi:10.1158/0008-5472.CAN-07-5836)
68. Girdler F, Gascoigne KE, Evers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS. 2006 Validating Aurora B as an anti-cancer drug target. *J. Cell Sci.* **119**, 3664–3675. (doi:10.1242/jcs.03145)
69. Tighe A, Johnson VL, Taylor SS. 2004 Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. *J. Cell Sci.* **117**, 6339–6353. (doi:10.1242/jcs.01556)
70. Bennett A, Bechi B, Tighe A, Thompson S, Procter DJ, Taylor SS. 2015 Cenp-E inhibitor GSK923295: novel synthetic route and use as a tool to generate aneuploidy. *Oncotarget* **6**, 20 921–20 932. (doi:10.18632/oncotarget.4879)
71. Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL. 2008 DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. *FASEB J.* **22**, 2243–2252. (doi:10.1096/fj.07-099234)
72. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H. 2008 A versatile nanotrapp for biochemical and functional studies with fluorescent fusion proteins. *Mol. Cell Proteomics* **7**, 282–289. (doi:10.1074/mcp.M700342-MCP200)
73. Westhorpe FG, Diez MA, Gurden MD, Tighe A, Taylor SS. 2010 Re-evaluating the role of Tao1 in the spindle checkpoint. *Chromosoma* **119**, 371–379. (doi:10.1007/s00412-010-0261-1)